PMID- 24050827
OWN - NLM
STAT- MEDLINE
DA  - 20131008
DCOM- 20140703
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 132
IP  - 4
DP  - 2013 Oct
TI  - Recombinant thrombomodulin improved Stevens-Johnson syndrome with high serum
      high-mobility group-B1 DNA-binding protein induced by lenalidomide administered
      to treat multiple myeloma.
PG  - 493-4
LID - 10.1016/j.thromres.2013.08.020 [doi]
LID - S0049-3848(13)00375-7 [pii]
FAU - Inoue, Yasuyuki
AU  - Inoue Y
AD  - Division of Hematology and Oncology, Department of Internal Medicine, St.
      Marianna University School of Medicine, Kawasaki, Japan. Electronic address:
      ino-yasu@marianna-u.ac.jp.
FAU - Saito, Tasuku
AU  - Saito T
FAU - Tsuruoka, Yuka
AU  - Tsuruoka Y
FAU - Sato, Kazuyuki
AU  - Sato K
FAU - Nishio, Yuji
AU  - Nishio Y
FAU - Suzuki, Yoshinori
AU  - Suzuki Y
FAU - Kato, Masayuki
AU  - Kato M
FAU - Isobe, Yasushi
AU  - Isobe Y
FAU - Sakai, Hirotaka
AU  - Sakai H
FAU - Takahashi, Masatomo
AU  - Takahashi M
FAU - Miura, Ikuo
AU  - Miura I
LA  - eng
PT  - Case Reports
PT  - Letter
DEP - 20130901
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (HMGB1 Protein)
RN  - 0 (HMGB1 protein, human)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Thrombomodulin)
RN  - 191732-72-6 (lenalidomide)
RN  - 4Z8R6ORS6L (Thalidomide)
SB  - IM
MH  - HMGB1 Protein/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*drug therapy
MH  - Recombinant Proteins/therapeutic use
MH  - Stevens-Johnson Syndrome/*blood/*drug therapy/etiology
MH  - Thalidomide/adverse effects/*analogs & derivatives/therapeutic use
MH  - Thrombomodulin/*therapeutic use
EDAT- 2013/09/21 06:00
MHDA- 2014/07/06 06:00
CRDT- 2013/09/21 06:00
PHST- 2013/05/21 [received]
PHST- 2013/07/19 [revised]
PHST- 2013/08/27 [accepted]
PHST- 2013/09/01 [aheadofprint]
AID - S0049-3848(13)00375-7 [pii]
AID - 10.1016/j.thromres.2013.08.020 [doi]
PST - ppublish
SO  - Thromb Res. 2013 Oct;132(4):493-4. doi: 10.1016/j.thromres.2013.08.020. Epub 2013
      Sep 1.